Xilio Therapeutics
28 hedge funds and large institutions have $42.8M invested in Xilio Therapeutics in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 2 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
3% less capital inflows, than outflows
Capital inflows: $1.33M | Capital outflows: $1.37M
2.48% less ownership
Funds ownership: 60.46% → 57.98% (-2.5%)
3% less funds holding
Funds holding: 29 → 28 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$562K |
| 2 |
Bridgeway Capital Management
Houston,
Texas
|
+$82.9K |
| 3 |
Morgan Stanley
New York
|
+$45.2K |
| 4 |
Renaissance Technologies
New York
|
+$20.7K |
| 5 |
BlackRock
New York
|
+$7.42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$752K |
| 2 |
Soleus Capital Management
Greenwich,
Connecticut
|
-$546K |
| 3 |
E
Ergoteles
New York
|
-$38K |
| 4 |
RBF Capital
San Francisco,
California
|
-$29K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.83K |
XLO Hedge Fund Activity: Q4 2022 in Review
28 of the 6,243 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q4 2022, worth a combined $42.8M — down 11% from $48.3M a quarter earlier.
Fund positioning in XLO was balanced in Q4 2022: 2 funds opened new positions, 2 closed out, 7 added to existing stakes and 4 trimmed.
The largest buyer was Bank of America, opening a new position worth an estimated $562K. The largest seller was Fidelity Investments, cutting an estimated $752K.
- 28 institutional investors held Xilio Therapeutics (XLO) as of Q4 2022, down from 29 in Q3 2022.
- Funds reported $42.8M of Xilio Therapeutics stock for Q4 2022, down 11% quarter-over-quarter.
- 2 funds opened new Xilio Therapeutics positions in Q4 2022 and 2 closed out, a net change of 0 holders.
- The largest Xilio Therapeutics buyer in Q4 2022 was Bank of America, an estimated $562K added.
- The largest Xilio Therapeutics seller in Q4 2022 was Fidelity Investments, an estimated $752K sold.
Based on aggregated 13F filings for Q4 2022.